NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes

Tuesday, September 20, 2022 - 12:00
Industrial Solutions
NorthStar is further expanding commercial-scale domestic radioisotope production capabilities using IBA’s environmentally preferable Rhodotron® accelerator technology

Louvain-La-Neuve, Belgium, and BELOIT, Wisconsin, USA September 20, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a new agreement under which NorthStar will purchase two additional Rhodotron® TT300 HE electron beam accelerators, and the associated beamlines, from IBA for the production of molybdenum-99 (Mo-99).

Read the full Press Release in the PDF below

Back to news